EUVIMED · CrossrefJournal
The Oncologist
ISSN 1083-7159 · Oxford University Press (OUP)
Latest articles
RWE: what is its regulatory fate?
Real-World LAG3 Expression as A Biomarker in Advanced Melanoma: Implications for Treatment Selection
Patient-reported outcomes from ASCENT-03: sacituzumab govitecan vs chemotherapy in advanced triple-negative breast cancer
A prospective trial of a personalized exercise program in patients with advanced prostate cancer
Treatment Hotspots and Controversies in Papillary Thyroid Microcarcinoma
Cholesterol transporters and immune-metabolic features in patients with metastatic renal cell carcinoma receiving immunotherapy combinations
National Gaps in Appendiceal Cancer Care and Implementation of a Regional Virtual Multidisciplinary Care Conference
TAVO412, an Anti-EGFR, cMET and VEGF Trispecific Antibody: Initial Results from a Phase I Dose Escalation Study in Patients with Advanced Solid Tumors
Tumor Longevity: a time-dependent biomarker of immune checkpoint inhibitor responsiveness across head and neck, lung, renal and urothelial cancers
A phase 2 study of tipifarnib in children and young adults with tumors harboring HRAS genomic alterations: NCI-COG Pediatric MATCH trial (APEC1621M)
Correction to: Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies
Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma
Sequential therapy with anlotinib and radioiodine for distant metastatic differentiated thyroid cancer: a phase II clinical trial
Pelvic insufficiency fractures after chemoradiotherapy for cervical cancer: incidence, long-term outcomes, and survivorship management
A novel referral system to optimize timing to specialized palliative care in patients with advanced cancer: an interventional study
Gabapentinoids for oncologic pruritus: a retrospective cohort study
Rethinking radiation therapy in the era of RAS inhibition for pancreatic cancer
Real-world treatment patterns and survival outcomes in extensive-stage small cell lung cancer across first-line induction and maintenance therapy
Behind every subject line
Peri-treatment Creatinine-Based eGFR Trajectories in Patients Receiving Breast Radiotherapy: A Retrospective Cohort Study
Immunotherapy and cancer: the CIPOMO viewpoint on challenges and opportunities
Clinical and Molecular Evolution During Panitumumab-Containing Therapy in EGFR-Amplified Esophagogastric Adenocarcinoma
Pembrolizumab combined with disitamab vedotin in human epidermal growth factor receptor 2-positive metastatic colorectal cancer
Whole-genome sequencing-based tumor-informed circulating tumor DNA monitoring for early detection of recurrence in patients with solid tumors
Exceptional long-term responses in metastatic androgen pathway-modulation sensitive prostate cancer
Hormone receptor–positive HER2-negative oligometastatic breast cancer: prognostic stratification and pattern of progression
A randomized phase II study of fulvestrant with or without ganetespib in patients with endocrine-resistant metastatic breast cancer
Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results
Long-term efficacy, clinical outcomes, and safety of vimseltinib in patients with tenosynovial giant cell tumor: results from the MOTION phase 3 trial
Real-world comparative effectiveness of FOLFOX, FOLFIRI, and CapOx as second-line chemotherapy for advanced biliary tract cancer
Volumes
2026 · 3872025 · 6742024 · 4062023 · 3272022 · 2862021 · 4652020 · 4482019 · 4152018 · 2592017 · 2392016 · 2342015 · 2602014 · 2162013 · 2492012 · 2542011 · 2552010 · 2082009 · 1752008 · 1952007 · 1902006 · 1582005 · 1392004 · 1292003 · 1152002 · 1622001 · 1512000 · 1151999 · 691998 · 681997 · 861996 · 70
EUVIMED